Cargando…

Tryptophan-Degrading Enzymes in Tumoral Immune Resistance

Tryptophan is required for T lymphocyte effector functions. Its degradation is one of the mechanisms selected by tumors to resist immune destruction. Two enzymes, tryptophan-2,3-dioxygenase and indoleamine 2,3-dioxygenase 1, control tryptophan degradation through the kynurenine pathway. A third prot...

Descripción completa

Detalles Bibliográficos
Autores principales: van Baren, Nicolas, Van den Eynde, Benoît J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315104/
https://www.ncbi.nlm.nih.gov/pubmed/25691885
http://dx.doi.org/10.3389/fimmu.2015.00034
_version_ 1782355430024937472
author van Baren, Nicolas
Van den Eynde, Benoît J.
author_facet van Baren, Nicolas
Van den Eynde, Benoît J.
author_sort van Baren, Nicolas
collection PubMed
description Tryptophan is required for T lymphocyte effector functions. Its degradation is one of the mechanisms selected by tumors to resist immune destruction. Two enzymes, tryptophan-2,3-dioxygenase and indoleamine 2,3-dioxygenase 1, control tryptophan degradation through the kynurenine pathway. A third protein, indoleamine 2,3-dioxygenase 2, was identified more recently. All three enzymes were reported to be expressed in tumors, and are candidate targets for pharmacological inhibition aimed at restoring effective anti-tumoral immunity. In this review, we compare these three enzymes in terms of structure, activity, regulation, and expression in healthy and cancerous tissues, in order to appreciate their relevance to tumoral immune resistance.
format Online
Article
Text
id pubmed-4315104
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-43151042015-02-17 Tryptophan-Degrading Enzymes in Tumoral Immune Resistance van Baren, Nicolas Van den Eynde, Benoît J. Front Immunol Immunology Tryptophan is required for T lymphocyte effector functions. Its degradation is one of the mechanisms selected by tumors to resist immune destruction. Two enzymes, tryptophan-2,3-dioxygenase and indoleamine 2,3-dioxygenase 1, control tryptophan degradation through the kynurenine pathway. A third protein, indoleamine 2,3-dioxygenase 2, was identified more recently. All three enzymes were reported to be expressed in tumors, and are candidate targets for pharmacological inhibition aimed at restoring effective anti-tumoral immunity. In this review, we compare these three enzymes in terms of structure, activity, regulation, and expression in healthy and cancerous tissues, in order to appreciate their relevance to tumoral immune resistance. Frontiers Media S.A. 2015-02-03 /pmc/articles/PMC4315104/ /pubmed/25691885 http://dx.doi.org/10.3389/fimmu.2015.00034 Text en Copyright © 2015 van Baren and Van den Eynde. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
van Baren, Nicolas
Van den Eynde, Benoît J.
Tryptophan-Degrading Enzymes in Tumoral Immune Resistance
title Tryptophan-Degrading Enzymes in Tumoral Immune Resistance
title_full Tryptophan-Degrading Enzymes in Tumoral Immune Resistance
title_fullStr Tryptophan-Degrading Enzymes in Tumoral Immune Resistance
title_full_unstemmed Tryptophan-Degrading Enzymes in Tumoral Immune Resistance
title_short Tryptophan-Degrading Enzymes in Tumoral Immune Resistance
title_sort tryptophan-degrading enzymes in tumoral immune resistance
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315104/
https://www.ncbi.nlm.nih.gov/pubmed/25691885
http://dx.doi.org/10.3389/fimmu.2015.00034
work_keys_str_mv AT vanbarennicolas tryptophandegradingenzymesintumoralimmuneresistance
AT vandeneyndebenoitj tryptophandegradingenzymesintumoralimmuneresistance